The BCR-ABL inhibitor imatinib was the first targeted therapy approved for the treatment of CML, and the first protein kinase inhibitor approved as a cancer treatment [1,97]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.